What is Adbry (tralokinumab-ldrm) for?
Adbry (tralokinumab-ldrm) is an interleukin-13 antagonist indicated to treat adults with moderate-to-severe atopic dermatitis (eczema) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. This medicine can be used with or without topical corticosteroids.
It is available in syringe form for injection, each containing 150 mg/ml tralokinumab-ldrm.
How does Adbry (tralokinumab-ldrm) work?
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin condition in which the body’s immune system attacks healthy skin cells.
The active substance in Adbry, tralokinumab, binds to the cytokine interleukin-13 (IL-13). IL-13 is a protein that is found to be increased in the skin of patients with atopic dermatitis. By blocking IL-13’s action, Adbry helps reduce the inflammation and other symptoms of atopic dermatitis.
Where has Adbry (tralokinumab-ldrm) been approved?
Adbry (tralokinumab-ldrm) was approved for the treatment of adults with atopic dermatitis by:
- The Food and Drug Administration (FDA), USA on December 28, 2021.
Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team.
How is Adbry (tralokinumab-ldrm) taken?
The standard dosage is:
- A starting dose of 600 mg (four 150 mg injections), followed by 300 mg (two 150 mg injections) given every other week
- After 16 weeks of treatment: patients with body weight <100 kg who achieve clear or almost clear skin may consider a dosage of 300 mg every 4 weeks
The injections are given under the skin (subcutaneously).
Adbry can be used with or without topical corticosteroids.
If you miss a dose of Adbry (tralokinumab-ldrm), take the next dose at your regular scheduled time.
Complete information about Adbry (tralokinumab-ldrm) dosage (preparation) and administration can be found in the official prescribing information listed in our references section.
Note: Please consult with your treating doctor for personalised dosing.
Are there any known adverse reactions or side effects of Adbry (tralokinumab-ldrm)?
Common adverse reactions
The most common side effects (≥1% of patients) listed in the prescribing information include:
- Upper respiratory tract infections
- Eye and eyelid inflammation, including redness, swelling, and itching (conjunctivitis)
- Injection site reactions
- High count of a certain white blood cell (eosinophilia)
Serious adverse reactions
The serious adverse reactions listed in the prescribing information include:
- Allergic reactions (hypersensitivity)
- Eye problems
Use in a specific population
It is not known whether Adbry (tralokinumab-ldrm) will harm your unborn baby. It is not known whether Adbry passes into your breast milk and if it can harm your child. Please discuss with your treating doctor if you are pregnant or breastfeeding, or planning to.
You should not receive a “live vaccine” during treatment with Adbry.
Tell your treating doctor about all your medical conditions, including if you have eye problems or have a parasitic (helminth) infection.
For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information.
1. Full prescribing information [FDA]: Adbry (tralokinumab-ldrm) [PDF]
Leo Pharma, Dec 2021
2. Adbry Mechanism of Action
Adbryhcp.com, cited Jan 2022
3. Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb
Wollenberg, A et al., Journal of Allergy and Clinical Immunology, Jan 2019